Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 142

Cited In for PubMed (Select 16622122)

1.

Risk Classification with an Adaptive Naive Bayes Kernel Machine Model.

Minnier J, Yuan M, Liu JS, Cai T.

J Am Stat Assoc. 2015 Apr 22;110(509):393-404.

PMID:
26236061
3.

Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators.

Strobl AN, Vickers AJ, Van Calster B, Steyerberg E, Leach RJ, Thompson IM, Ankerst DP.

J Biomed Inform. 2015 Aug;56:87-93. doi: 10.1016/j.jbi.2015.05.001. Epub 2015 May 16.

PMID:
25989018
4.

MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.

Casanova-Salas I, Masiá E, Armiñán A, Calatrava A, Mancarella C, Rubio-Briones J, Scotlandi K, Vicent MJ, López-Guerrero JA.

PLoS One. 2015 May 13;10(5):e0125576. doi: 10.1371/journal.pone.0125576. eCollection 2015.

5.

The impact of covariate measurement error on risk prediction.

Khudyakov P, Gorfine M, Zucker D, Spiegelman D.

Stat Med. 2015 Jul 10;34(15):2353-67. doi: 10.1002/sim.6498. Epub 2015 Apr 10.

PMID:
25865315
6.

Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Nieboer D, Vergouwe Y, Roobol MJ, Ankerst DP, Kattan MW, Vickers AJ, Steyerberg EW; Prostate Biopsy Collaborative Group.

J Clin Epidemiol. 2015 Apr;68(4):426-34. doi: 10.1016/j.jclinepi.2014.11.022. Epub 2014 Nov 29.

PMID:
25777297
7.

JNCI and cancer prevention.

Dunn BK, Ghosh S, Kramer BS.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: djv021. doi: 10.1093/jnci/djv021. Print 2015 Mar.

PMID:
25713150
8.

The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape.

Strobl AN, Thompson IM, Vickers AJ, Ankerst DP.

J Urol. 2015 Jul;194(1):58-64. doi: 10.1016/j.juro.2015.01.092. Epub 2015 Jan 28.

PMID:
25636656
9.

Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.

Walsh AL, Considine SW, Thomas AZ, Lynch TH, Manecksha RP.

Br J Gen Pract. 2014 Dec;64(629):e783-7. doi: 10.3399/bjgp14X682861.

10.

Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Wei JT, Feng Z, Partin AW, Brown E, Thompson I, Sokoll L, Chan DW, Lotan Y, Kibel AS, Busby JE, Bidair M, Lin DW, Taneja SS, Viterbo R, Joon AY, Dahlgren J, Kagan J, Srivastava S, Sanda MG.

J Clin Oncol. 2014 Dec 20;32(36):4066-72. doi: 10.1200/JCO.2013.52.8505. Epub 2014 Nov 10.

PMID:
25385735
11.

Network analysis of ChIP-Seq data reveals key genes in prostate cancer.

Zhang Y, Huang Z, Zhu Z, Liu J, Zheng X, Zhang Y.

Eur J Med Res. 2014 Sep 3;19:47. doi: 10.1186/s40001-014-0047-7.

12.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

PMID:
25168616
13.

Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting.

Lim J, Bhoo-Pathy N, Sothilingam S, Malek R, Sundram M, Hisham Bahadzor B, Ong TA, Ng KL, Sivalingam S, Razack AH.

PLoS One. 2014 Aug 11;9(8):e104917. doi: 10.1371/journal.pone.0104917. eCollection 2014.

14.
15.
16.

Risk stratification of prostate cancer patients based on EPS-urine zinc content.

Medarova Z, Ghosh SK, Vangel M, Drake R, Moore A.

Am J Cancer Res. 2014 Jul 16;4(4):385-93. eCollection 2014.

17.

Nomogram to predict prostate cancer diagnosis on primary transrectal ultrasound-guided prostate biopsy in a contemporary series.

DiBlasio CJ, Derweesh IH, Maddox MM, Mehrazin R, Yu C, Malcolm JB, Aleman MA, Patterson AL, Wake RW, Kattan MW.

Curr Urol. 2013 Jan;6(3):141-5. doi: 10.1159/000343528. Epub 2012 Dec 21.

18.

Andropause: Current concepts.

Singh P.

Indian J Endocrinol Metab. 2013 Dec;17(Suppl 3):S621-9. doi: 10.4103/2230-8210.123552. Review.

19.

The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort.

Gaines AR, Turner EL, Moorman PG, Freedland SJ, Keto CJ, McPhail ME, Grant DJ, Vidal AC, Hoyo C.

Cancer Causes Control. 2014 Aug;25(8):1029-35. doi: 10.1007/s10552-014-0402-6. Epub 2014 May 31.

20.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, Sokoll LJ, Sanda MG, Wei JT, Leach RJ, Thompson IM.

Urology. 2014 Jun;83(6):1362-7. doi: 10.1016/j.urology.2014.02.035.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk